Literature DB >> 27885498

Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.

Ayako Chida1,2, Kei Inai2, Hiroki Sato3, Eriko Shimada2, Tsutomu Nishizawa4, Mitsuyo Shimada2, Michiko Furutani2, Yoshiyuki Furutani2, Yoichi Kawamura1, Masaya Sugimoto5, Jun Ishihara6, Masako Fujiwara7, Takashi Soga8, Masatoshi Kawana9, Shinya Fuji10, Shigeru Tateno11, Kenji Kuraishi12, Shigetoyo Kogaki13, Mitsuhiro Nishimura14, Mamoru Ayusawa15, Fukiko Ichida16, Hirokuni Yamazawa17, Rumiko Matsuoka4,18, Shigeaki Nonoyama1, Toshio Nakanishi19.   

Abstract

Although some studies have attempted to find useful prognostic factors in hypertrophic cardiomyopathy (HCM), those results are not fully helpful for use in actual clinical practice. Furthermore, several genetic abnormalities associated with HCM have been identified. However, the genotype-phenotype correlation in HCM remains to be elucidated. Here, we attempted to assess patients with different types of gene mutations causing HCM and investigate the prognosis. A total of 140 patients with HCM underwent a screening test for myofilament gene mutations by direct sequencing of eight sarcomeric genes. Patients with a single mutation in cardiac troponin T, cardiac troponin I, α-tropomyosin, and regulatory and essential light chains were excluded from the study because the number of cases was too small. The clinical presentations and outcomes of the remaining 127 patients with HCM, 31 β-myosin heavy chain (MYH7) mutation carriers, 19 cardiac myosin-binding protein C (MYBPC3) mutation carriers, and 77 mutation non-carriers were analyzed retrospectively. MYBPC3 mutation carriers had a high frequency of ventricular arrhythmia and syncope. Kaplan-Meier curves revealed no significant difference in prognosis among the three groups, but a lack of family history of sudden death (SD) and a past history of syncope were significantly related to poor prognosis. An absence of family history of SD and past history of syncope are useful prognostic factors in patients with HCM. MYH7 and MYBPC3 mutations did not significantly influence prognosis compared to non-carriers. However, patients with the MYBPC3 mutation should be closely followed for the possibility of SD.

Entities:  

Keywords:  Gene mutation; Genotype–phenotype; HCM; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27885498     DOI: 10.1007/s00380-016-0920-0

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  50 in total

1.  A novel deletion mutation in the cardiac myosin-binding protein C gene as a cause of Maron's type IV hypertrophic cardiomyopathy.

Authors:  Ryuichiro Anan; Hideshi Niimura; Shinichi Minagoe; Chuwa Tei
Journal:  Am J Cardiol       Date:  2002-02-15       Impact factor: 2.778

2.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.

Authors:  H Watkins; A Rosenzweig; D S Hwang; T Levi; W McKenna; C E Seidman; J G Seidman
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

3.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Vlad C Vasile; Steve R Ommen; Melissa L Will; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

4.  Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy.

Authors:  Julia Daher Carneiro Marsiglia; Flávia Laghi Credidio; Théo Gremen Mimary de Oliveira; Rafael Ferreira Reis; Murillo de Oliveira Antunes; Aloir Queiroz de Araujo; Rodrigo Pinto Pedrosa; João Marcos Bemfica Barbosa-Ferreira; Charles Mady; José Eduardo Krieger; Edmundo Arteaga-Fernandez; Alexandre da Costa Pereira
Journal:  Am Heart J       Date:  2013-09-18       Impact factor: 4.749

5.  Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Erik G Ellsworth; Steve R Ommen; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

6.  Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes.

Authors:  A Rosenzweig; H Watkins; D S Hwang; M Miri; W McKenna; T A Traill; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  1991-12-19       Impact factor: 91.245

7.  Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy.

Authors:  R Anan; G Greve; L Thierfelder; H Watkins; W J McKenna; S Solomon; C Vecchio; H Shono; S Nakao; H Tanaka
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

Review 8.  Genetics of hypertrophic cardiomyopathy: one, two, or more diseases?

Authors:  J Martijn Bos; Steve R Ommen; Michael J Ackerman
Journal:  Curr Opin Cardiol       Date:  2007-05       Impact factor: 2.161

9.  Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy.

Authors:  Elena Biagini; Iacopo Olivotto; Maria Iascone; Maria I Parodi; Francesca Girolami; Giulia Frisso; Camillo Autore; Giuseppe Limongelli; Massimiliano Cecconi; Barry J Maron; Martin S Maron; Stefania Rosmini; Francesco Formisano; Beatrice Musumeci; Franco Cecchi; Attilio Iacovoni; Tammy S Haas; Maria L Bacchi Reggiani; Paolo Ferrazzi; Francesco Salvatore; Paolo Spirito; Claudio Rapezzi
Journal:  Am J Cardiol       Date:  2014-06-19       Impact factor: 2.778

10.  Mutations in the cardiac troponin T gene show various prognoses in Japanese patients with hypertrophic cardiomyopathy.

Authors:  Etsuko Fujita; Toshio Nakanishi; Tsutomu Nishizawa; Nobuhisa Hagiwara; Rumiko Matsuoka
Journal:  Heart Vessels       Date:  2013-03-14       Impact factor: 2.037

View more
  6 in total

Review 1.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

2.  2D speckle-tracking TTE-based quantitative classification of left ventricular myocardium in patients with hypertrophic cardiomyopathy by the presence or the absence of fibrosis and/or hypertrophy.

Authors:  Nobusada Funabashi; Hiroyuki Takaoka; Koya Ozawa; Masae Uehara; Issei Komuro; Yoshio Kobayashi
Journal:  Heart Vessels       Date:  2018-03-22       Impact factor: 2.037

3.  Double missense mutations in cardiac myosin-binding protein C and myopalladin genes: A case report with diffuse coronary disease, complete atrioventricular block, and progression to dilated cardiomyopathy.

Authors:  Sandra Mastroianno; Pietro Palumbo; Stefano Castellana; Maria Pia Leone; Raimondo Massaro; Domenico Rosario Potenza; Tommaso Mazza; Aldo Russo; Marco Castori; Massimo Carella; Giuseppe Di Stolfo
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-09-16       Impact factor: 1.468

4.  Diagnostic validity and clinical utility of genetic testing for hypertrophic cardiomyopathy: a systematic review and meta-analysis.

Authors:  Susan Christian; Allison Cirino; Brittany Hansen; Stephanie Harris; Andrea M Murad; Jaime L Natoli; Jennifer Malinowski; Melissa A Kelly
Journal:  Open Heart       Date:  2022-04

Review 5.  Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside.

Authors:  Hua Shen; Shi-Yong Dong; Ming-Shi Ren; Rong Wang
Journal:  Front Cardiovasc Med       Date:  2022-08-18

6.  A Wide and Specific Spectrum of Genetic Variants and Genotype-Phenotype Correlations Revealed by Next-Generation Sequencing in Patients with Left Ventricular Noncompaction.

Authors:  Ce Wang; Yukiko Hata; Keiichi Hirono; Asami Takasaki; Sayaka Watanabe Ozawa; Hideyuki Nakaoka; Kazuyoshi Saito; Nariaki Miyao; Mako Okabe; Keijiro Ibuki; Naoki Nishida; Hideki Origasa; Xianyi Yu; Neil E Bowles; Fukiko Ichida
Journal:  J Am Heart Assoc       Date:  2017-08-30       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.